carry out ongoing somatic hypermutation and class-switch recombination subsequent to activation-induced deaminase (AID) expression much as in germinal center cells (6, 10 ). An inverse correlation of Zap70 or CD38 expression has also been exploited for use in the clinical setting in order to distinguish B-CLLs of differing severity (11) (12) (13) . Recent studies of gene expression and surface phenotype of B-CLL cells have revealed that most have a memory B cell phenotype (14, 15) regardless of mutation status. While it is possible that B-CLLs originate from an antigen-exposed memory B cell population, it is also conceivable that memory cell characteristics are acquired following transformation. (17) found an increased use of unmutated V H 1-69 rearrangements in patients with IgM + BCLLs that had a restricted set of D H and J H 6 gene segments, but later these segments were not found to be increased in normal blood (21) . While still unclear, it is possible that individual or tissue-specific gene segment distributions in aging individuals have a role in particular antigen interactions of B-CLL clones.
Clonotypic Igs are seen in other disease processes
Other immunological diseases that have similar widespread clonotypic Ig manifestations have also been shown to be associated with infection or antigen. One such example is essential mixed cryoglobulinemia (EMC), in which monoclonal IgM antibodies are reactive to polyclonal IgG at temperatures lower than 37°C. Long after EMC was discovered, it was found to be associated with hepatitis C virus (HCV) infection (22, 23) and often makes use of the V H 1-69 gene segment, as do responses to HCV (24) . B-CLL is not associated with HCV infection (25) , but the antigeninduced expansion of clonotypic B cells may be similar. Over twenty-five years ago, our laboratory showed that the similarity among heavy chain complementaritydetermining regions (CDRs) 2 and 3 in the mixed cryoglobulin rheumatoid factors Pom and Lay (26, 27) was perhaps an early hint of similar results to those reported by Ghiotto et al. in this issue (16) . EMC now is thought to arise from CD5 -immunocytomas that are considered marginal zone lymphomas. It is noteworthy that one of the patients described by Ghiotto et al. was identified as an immunocytoma case. Indeed, monoclonal cryoglobulins are often associated with underlying B-CLL or other lymphoproliferative diseases. In the subset of IgG + B-CLL sequences reported in the study by Ghiotto et al., the CDR3 amino acid sequences are nearly identical, lending the possibility that they arise as a result of similar mechanisms.
Foreign or autoantigens may play a role in B-CLL
It remains to be determined, however, in the case of B-CLL whether a foreign or autoantigen is involved and what role it plays in the progression of the disease (Figure 1) . The similarity of Ig clones that have been encountered in the Ghiotto et al. study (16) may provide an important clue to the identification of the antigen. Using Ars as an immunogen, our laboratory showed many years ago that the same Ig rearrangements were used in response to this very small hapten in spite of being isolated from different (albeit genetically identical) mice (28) (29) (30) (31) . Such findings have been reported in other systems involving immunization with small haptens. In the arsonate system, the amino acid junction sequences of the rearrangements were identical, and an arginine residue at position 99 of the light chain VJ junction of anti-Ars antibodies was shown to be essential for the antibody to recognize this hapten (32) . While certain gene segments have been commonly associated with B-CLL (indeed, this led to the discovery of the VH5 gene segment family, ref. 33), the primary structure of the B cell receptor in B-CLL, particularly IgG clones, appears to be more restricted than has previously been thought. There is ample evidence of highly restricted immune responses from the mouse myelomas to carbohydrates (34) , raising the possibility that clonal populations in B-CLL patients may be specific for carbohydrate antigens. Marginal zone B cells appear to be important for polysaccharide responses (35) (36) (37) (38) and may be involved in the development of B-CLL.
Ghiotto et al. (16) discuss features of the antigen-binding domain of the B-CLL clones that were visualized by homology modeling. The remarkable similarity among the entire rearrangement and heavylight chain combinations also resembles those seen in several model systems in responses to small haptens. Of particular interest is a conserved arginine in the base of the binding pocket (which is the result of a recombination) much like that seen in anti-Ars responses in mice. A prominent bulge on the side of three of the five heavychain CDR3s was also evident and may pro- vide an unusual surface for an antibodyantigen interaction.
Studies concerning the role and nature of antigens involved in the natural history of B-CLL will clearly have important clinical implications. B-CLLs appear to originate from existing cells, perhaps in the marginal zone, that have special cell phenotypes, producing antibodies against what is likely a very small ligand. Chronic antigenic stimulation of a defined subset of B cells may play an important role in the development of B-CLL pathogenesis. It is possible that individuals have different genetic predispositions, due to polymorphic variations in their immunoglobulin loci, to developing B-CLL clonal expansions in response to certain antigens. Targeted vaccination or methods to maintain tolerance for particular autoantigens may play an important future role in preventative therapies. More practically, the presence of frequent types of rearrangements raises the possibility of developing antiidiotypic antibodies or even hapten/antigen-binding cytotoxic drugs that could be used for the targeted delivery of therapeutic agents to leukemic cells.
